Cefetamet pivoxil in otitis media

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology and Therapeutics
• Otolaryngology

Background:

• Acute otitis media (AOM) is a common childhood infection requiring effective antibiotic treatment.
• Evaluating alternative antibiotic regimens is crucial for optimizing AOM management and combating resistance.

Purpose of the Study:

• To compare the efficacy and safety of cefetamet pivoxil versus cefaclor in children with AOM.
• To assess bacteriological and clinical cure rates, as well as adverse event profiles.

Main Methods:

• Multicentre, open-label, randomized, parallel-group study involving 270 children aged 1-15 years.
• Patients received either cefetamet pivoxil (10 mg/kg b.i.d.) or cefaclor (13.5 mg/kg t.i.d.) for 7 days.
• Outcomes included bacteriological and clinical cure rates, and incidence of adverse events.

Main Results:

• Cefetamet pivoxil achieved 100% bacteriological cure (44/44) compared to 86% (24/28) for cefaclor.
• Clinical cure or improvement was higher with cefetamet pivoxil (97%; 117/121) versus cefaclor (90%; 104/115).
• Cefetamet pivoxil showed a lower incidence of adverse events (11% vs. 15%) and fewer treatment withdrawals (0.7% vs. 2.2%).

Conclusions:

• Cefetamet pivoxil is a highly effective and well-tolerated treatment option for acute otitis media in children.
• The study supports cefetamet pivoxil as a favorable alternative to cefaclor for pediatric AOM management.